Product Information

CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.6208 per EA under NDC 16571069201. Its NADAC has been published 191 times since Jun 29, 2022.

CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB

CARBIDOPA, LEVODOPA AND ENTACAPONE
$0.6208per EA

Strength

31.25; 200; 125 mg/1; mg/1; mg/1

NDC

16571069201

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

6/17/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA213212

On Market Since

8/5/2021

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid
Catechol O-Methyltransferase Inhibitors
Catechol-O-Methyltransferase Inhibitor

Price Statistics

The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB has been published 191 times since Jun 29, 2022, and over the history we have for it it has declined 31.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6208 per EA
All-time high$1.0516 (Jul 12, 2023)
All-time low$0.6208 (Jun 17, 2026)
52-week high$0.7823
52-week low$0.6208
Median price$0.7823
Average price$0.8454
Largest weekly change+33.4% (Sep 20, 2023)
Weeks tracked191
Tracking sinceJun 29, 2022

Price History

1W

0.0%

1M

-7.5%

3M

-14.7%

6M

-20.6%

1Y

-14.4%

3Y

-41.0%

5Y

N/A

All

-31.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the CARBIDOPA, LEVODOPA AND ENTACAPONE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Frequently asked questions

What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.6208 per EA (NDC 16571069201), effective Jun 24, 2026.

How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB changed over time?

Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB has declined 31.9%. It has been tracked across 191 weekly CMS publications since Jun 29, 2022.

What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

Since Jun 29, 2022, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB has ranged from a low of $0.6208 (Jun 17, 2026) to a high of $1.0516 (Jul 12, 2023), with a median of $0.7823 per EA.

Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

No other NADAC-published product currently shares the active ingredient, strength, and dosage form of CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB, so no direct lower-cost alternative is listed.

Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB (NDC 16571069201) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.